Electrochemotherapy versus standard radiotherapy for the treatment of basal cell carcinoma

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519066-49-01

Enrollment

Registered

2024-12-16

Start date

2020-11-16

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basal cell carcinoma (non-melanoma skin cancer)

Brief summary

Effect of electhrochemotherapy versus standard radiotherapy for the treatment of basal cell carcinomas less than 3 cm.

Detailed description

Adverse events, Cosmesis, Patient satisfaction

Interventions

DRUGBleomycin ”Baxter”

DRUGpulver til injektions- og infusionsvæske

DRUGopløsning

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Effect of electhrochemotherapy versus standard radiotherapy for the treatment of basal cell carcinomas less than 3 cm.	—

Secondary

Measure	Time frame
Adverse events, Cosmesis, Patient satisfaction	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026